Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching from Rituximab to Ocrelizumab in Relapsing MS
NCT02980042Phase 3Completed
- Sponsor
- University of Colorado Denver
- Start
- Jan 2017
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ocrelizumab in multiple sclerosis (MS), sponsored by University of Colorado Denver. Started Jan 2017; status: completed.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02980042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02980042.